Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone.

Authors:
Ma HY; Vander Heiden JA; Uttarwar S; Xi Y; N'Diaye EN and 6 more

Journal:
Eur Respir J

Publication Year: 2023

DOI:
10.1183/13993003.00604-2022

PMCID:
PMC10133585

PMID:
36585256

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Eur Respir J

Abbreviation: Eur Respir J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory d…
Wang T; Duan W; Jia X and 4 more (2024) - Transparency Score: 3/6
CPAP resumption after a first termination and impact on all-cause mortality in France.
Pépin JL; Tamisier R; Benjafield AV and 9 more (2024) - Transparency Score: 3/6
Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, bu…
Kerem E; Orenti A; Adamoli A and 4 more (2024) - Transparency Score: 3/6
Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmo…
Houston CJ; Alkhatib A; Einarsson GG and 3 more (2024) - Transparency Score: 3/6
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in auto…
Campo I; Carey BC; Paracchini E and 11 more (2024) - Transparency Score: 5/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"this article has an editorial commentary: https://doi org/10 1183/13993003 00240-2023 data and code availability: rna-seq data has been deposited with the gene expression omnibus (geo) data repository under accession number gse226249."

Code Sharing
Evidence found in paper:

"Conflict of interest: All authors except P.J. Wolters are or were employees of Genentech/Roche."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025